- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Orca-T Proves Safe and Effective in Advanced Hematologic Malignancies
April 15th 2024, 7:00pm
The regulatory T cell enriched donor cell agent Orca-T was safe and displayed activity in the reduced intensity conditioning setting for patients with advanced hematologic malignancies.
Nadofaragene Firadenovec Showcases Sustained Responses in BCG-Unresponsive NMIBC
April 12th 2024, 1:47pm
The intravesical gene therapy elicited durable remissions in a high percentage of patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer.
Insider Insights: Unveiling Takeaways from AACR 2024
April 11th 2024, 6:54pm
Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.
Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma
April 10th 2024, 11:53pm
Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.
Savolitinib/Osimertinib Yields Responses in EGFR-Mutant, MET-Amplified, Osimertinib-Resistant NSCLC
April 10th 2024, 7:45pm
Responses with savolitinib plus osimertinib were higher in patients with NSCLC who had higher MET amplification cutoffs vs the overall population.
Novel CAR T-Cell Therapy HR001 Demonstrates Efficacy in R/R Non-Hodgkin Lymphoma
April 10th 2024, 4:42pm
The novel CAR T-cell agent HR001 was effective, with durable responses and a favorable safety profile observed, in relapsed/refractory non-Hodgkin lymphoma.
RGI-2001 Plus Tacrolimus/Methotrexate Demonstrates Protective Effect From Acute GVHD Post Allo-HSCT
April 10th 2024, 4:33pm
Prophylactic treatment with RGI-2001 plus tacrolimus and methotrexate led to a lower incidence of acute GVHD vs CIBMTR control following allo-HSCT.
PSMA-Directed Targeted Alpha Therapy Shows Activity in Heavily Pretreated Metastatic CRPC
April 10th 2024, 3:01pm
FPI-2265 showed promising activity in patients with metastatic castration-resistant prostate cancer which was similar to prior safety and efficacy data reported.
Proteogenomic Signatures Shed Light on Prostate Cancer Recurrence Risk in Select Ancestries
April 10th 2024, 1:25am
A proteomics analysis revealed significant variations in protein expression and informative markers between African vs European prostate tumors.
Dr Christenson on Copanlisib Plus Nivolumab in Pretreated PIK3Ca+ MSS mCRC
April 9th 2024, 10:57pm
Eric S. Christenson, MD, discusses efficacy data for copanlisib plus nivolumab in patients with pretreated, MSS metastatic colorectal cancer.
Investigational Vaccine TG4050 Shows Early Clinical Benefit in HPV– Head and Neck Cancers
April 9th 2024, 10:10pm
Phase 1 data of TG4050 elicited tumor-specific immune responses that resulted in low relapse rates in patients with resected HPV–negative head and neck cancers.
AZD1390 Demonstrates Initial Safety, May Enhance Radiotherapy Efficacy in Glioblastoma
April 9th 2024, 7:05pm
Early safety and efficacy data seen with AZD1390 in a phase 1 study indicate it's potential utility as a radiosensitizing treatment in glioblastoma.
Mirvetuximab Soravtansine Plus Pembrolizumab Makes a Splash in pMMR/MSS FRalpha+ Endometrial Cancer
April 9th 2024, 2:57pm
Mirvetuximab soravtansine plus pembrolizumab displays efficacy in recurrent or persistent, FRalpha-positive, pMMR/MSS serous endometrial cancer.
Dr Srour on the Safety and Efficacy of the Allogeneic CAR T-Cell Therapy CTX130 in Advanced ccRCC
April 9th 2024, 12:58am
Samer A. Srour, MB ChB, MS, discusses efficacy and safety data for the allogeneic CAR T-cell therapy CTX130 in advanced clear cell renal cell carcinoma.
Olaparib With Chemotherapy Does Not Elicit Improved Outcomes vs Chemotherapy Alone in BRCA Wild-Type TNBC
April 8th 2024, 9:53pm
Olaparib on a gap schedule with chemotherapy does not improve responses vs chemotherapy alone in the neoadjuvant setting for patients with BRCA wild-type TNBC.
Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial Cancer
April 8th 2024, 9:10pm
Rebecca L. Porter, MD, PhD, discusses the evaluation of mirvetuximab soravtansine plus pembrolizumab in FRα-positive, pMMR/MSS endometrial cancer.
Copanlisib Plus Nivolumab Demonstrates Activity in Microsatellite Stable Colorectal Cancer
April 8th 2024, 7:40pm
Copanlisib plus nivolumab was active and met the primary end point of a phase 1/2 study in a cohort of patients with MSS CRC.
Exosome-Based Assay Shows Diagnostic Sensitivity, Specificity in Pancreatic Cancer
April 8th 2024, 7:31pm
A microRNA assay combined with CA19-9 displayed diagnostic accuracy in the early detection of pancreatic cancer.
Saruparib Generates Early Efficacy and Safety Signals in HRR-Mutant Advanced Breast Cancer
April 8th 2024, 6:48pm
Saruparib's favorable activity and safety may allow patients with advanced solid tumors to stay on treatment longer vs other approved PARP inhibitors.